{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:05:43Z","timestamp":1787238343595,"version":"build-2736575974"},"reference-count":127,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000522","name":"The Company of Biologists","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000522","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002996","name":"Nederlandse Hartstichting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008666","name":"Fundaci\u00f3 la Marat\u00f3 de TV3","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Gobierno de Espa\u00f1a Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Basic to Translational Science"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jacbts.2024.04.005","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T14:53:28Z","timestamp":1718808808000},"page":"1360-1374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Targeting Soluble TGF-\u03b2 Factors"],"prefix":"10.1016","volume":"9","author":[{"given":"Clarissa","family":"Becher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Wits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances S.","family":"de Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Sanchez-Duffhues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9344-6746","authenticated-orcid":false,"given":"Marie-Jose","family":"Goumans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacbts.2024.04.005_bib1","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacbts.2024.04.005_bib2","doi-asserted-by":"crossref","first-page":"1801887","DOI":"10.1183\/13993003.01887-2018","article-title":"Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives","volume":"53","author":"Humbert","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacbts.2024.04.005_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01900-2018","article-title":"Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update","volume":"53","author":"Vonk Noordegraaf","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacbts.2024.04.005_bib4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrcardio.2017.84","article-title":"Epidemiology and treatment of pulmonary arterial hypertension","volume":"14","author":"Lau","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacbts.2024.04.005_bib5","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1378\/chest.11-1460","article-title":"An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry","volume":"142","author":"Benza","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jacbts.2024.04.005_bib6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1378\/chest.10-3114","article-title":"Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management","volume":"141","author":"Shapiro","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jacbts.2024.04.005_bib7","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/cvr\/cvad129","article-title":"Sex-biased TGF\u03b2 signalling in pulmonary arterial hypertension","volume":"119","author":"Wits","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacbts.2024.04.005_bib8","doi-asserted-by":"crossref","first-page":"a021873","DOI":"10.1101\/cshperspect.a021873","article-title":"TGF-\u03b2 and the TGF-\u03b2 family: context-dependent roles in cell and tissue physiology","volume":"8","author":"Morikawa","year":"2016","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.jacbts.2024.04.005_bib9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1101\/gad.8.2.133","article-title":"The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms","volume":"8","author":"Kingsley","year":"1994","journal-title":"Genes Dev"},{"key":"10.1016\/j.jacbts.2024.04.005_bib10","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jacc.2009.04.018","article-title":"Cellular and molecular basis of pulmonary arterial hypertension","volume":"54","author":"Morrell","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2024.04.005_bib11","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1242\/dev.000166","article-title":"Nodal signaling: developmental roles and regulation","volume":"134","author":"Shen","year":"2007","journal-title":"Development"},{"key":"10.1016\/j.jacbts.2024.04.005_bib12","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1128\/MCB.20.10.3742-3751.2000","article-title":"Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury","volume":"20","author":"Hsiao","year":"2000","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jacbts.2024.04.005_bib13","doi-asserted-by":"crossref","first-page":"a021881","DOI":"10.1101\/cshperspect.a021881","article-title":"Activins and inhibins: roles in development, physiology, and disease","volume":"8","author":"Namwanje","year":"2016","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.jacbts.2024.04.005_bib14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.mce.2003.09.012","article-title":"AMH signaling: from receptor to target gene","volume":"211","author":"Visser","year":"2003","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jacbts.2024.04.005_bib15","doi-asserted-by":"crossref","first-page":"a022103","DOI":"10.1101\/cshperspect.a022103","article-title":"Structural biology and evolution of the TGF-\u03b2 family","volume":"8","author":"Hinck","year":"2016","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.jacbts.2024.04.005_bib16","doi-asserted-by":"crossref","first-page":"115549","DOI":"10.1016\/j.bone.2020.115549","article-title":"Structural perspective of BMP ligands and signaling","volume":"140","author":"Gipson","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.jacbts.2024.04.005_bib17","doi-asserted-by":"crossref","first-page":"a021923","DOI":"10.1101\/cshperspect.a021923","article-title":"Agonists and antagonists of TGF-\u03b2 family ligands","volume":"8","author":"Chang","year":"2016","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.jacbts.2024.04.005_bib18","doi-asserted-by":"crossref","first-page":"10792","DOI":"10.1074\/jbc.M115.713487","article-title":"Transforming growth factor-\u03b2 family ligands can function as antagonists by competing for type II receptor binding","volume":"291","author":"Aykul","year":"2016","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jacbts.2024.04.005_bib19","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1146\/annurev.biochem.67.1.753","article-title":"TGF-\u03b2 signal transduction","volume":"67","author":"Massagu\u00e9","year":"1998","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.jacbts.2024.04.005_bib20","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood-2006-07-034124","article-title":"Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor\u2013like kinase 1 (ALK1) in endothelial cells","volume":"109","author":"David","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2024.04.005_bib21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/abbs\/gmx126","article-title":"TGF-\u03b2 family co-receptor function and signaling","volume":"50","author":"Nickel","year":"2018","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"10.1016\/j.jacbts.2024.04.005_bib22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0065-2776(00)75003-6","article-title":"TGF-\u03b2 signaling by Smad proteins","volume":"75","author":"Miyazono","year":"2000","journal-title":"Adv Immunol"},{"key":"10.1016\/j.jacbts.2024.04.005_bib23","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1101\/gad.1350705","article-title":"Smad transcription factors","volume":"19","author":"Massagu\u00e9","year":"2005","journal-title":"Genes Dev"},{"key":"10.1016\/j.jacbts.2024.04.005_bib24","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/cr.2008.328","article-title":"Non-Smad pathways in TGF-\u03b2 signaling","volume":"19","author":"Zhang","year":"2009","journal-title":"Cell Res"},{"key":"10.1016\/j.jacbts.2024.04.005_bib25","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3389\/fcell.2020.00260","article-title":"TGF-\u03b2\u2013induced endothelial to mesenchymal transition in disease and tissue engineering","volume":"8","author":"Ma","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.jacbts.2024.04.005_bib26","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/jcp.21126","article-title":"Activin receptor\u2013like kinase 1 inhibits human microvascular endothelial cell migration: potential roles for JNK and ERK","volume":"213","author":"David","year":"2007","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.jacbts.2024.04.005_bib27","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1124\/jpet.105.091249","article-title":"Transforming growth factor-beta-dependent growth inhibition in primary vascular smooth muscle cells is p38-dependent","volume":"315","author":"Seay","year":"2005","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jacbts.2024.04.005_bib28","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/79226","article-title":"Heterozygous germline mutations in BMPR2, encoding a TGF-\u03b2 receptor, cause familial primary pulmonary hypertension","volume":"26","author":"Lane","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacbts.2024.04.005_bib29","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1161\/01.CIR.0000012754.72951.3D","article-title":"Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor","volume":"105","author":"Atkinson","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2024.04.005_bib30","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/jmg.40.12.865","article-title":"Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia","volume":"40","author":"Harrison","year":"2003","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.jacbts.2024.04.005_bib31","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/thx.2003.11890","article-title":"Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension","volume":"59","author":"Chaouat","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.jacbts.2024.04.005_bib32","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1161\/CIRCGENETICS.111.961888","article-title":"Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension","volume":"5","author":"Austin","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jacbts.2024.04.005_bib33","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/humu.21605","article-title":"Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension","volume":"32","author":"Nasim","year":"2011","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jacbts.2024.04.005_bib34","doi-asserted-by":"crossref","first-page":"1801609","DOI":"10.1183\/13993003.01609-2018","article-title":"Germline BMP9 mutation causes idiopathic pulmonary arterial hypertension","volume":"53","author":"Wang","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacbts.2024.04.005_bib35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1161\/01.CIR.0000102381.57477.50","article-title":"Endothelial dysfunction in pulmonary hypertension","volume":"109","author":"Budhiraja","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2024.04.005_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18102157","article-title":"TGF-\u03b2\u2013induced endothelial-mesenchymal transition in fibrotic diseases","volume":"18","author":"Pardali","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacbts.2024.04.005_bib37","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.3390\/ijms19092585","article-title":"TGF-\u03b2 and BMPR2 signaling in PAH: two black sheep in one family","volume":"19","author":"Rol","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacbts.2024.04.005_bib38","doi-asserted-by":"crossref","first-page":"e3000557","DOI":"10.1371\/journal.pbio.3000557","article-title":"BMPR2 acts as a gatekeeper to protect endothelial cells from increased TGF\u03b2 responses and altered cell mechanics","volume":"17","author":"Hiepen","year":"2019","journal-title":"PLoS Biol"},{"key":"10.1016\/j.jacbts.2024.04.005_bib39","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/path.5193","article-title":"Inflammation induces endothelial-to-mesenchymal transition and promotes vascular calcification through downregulation of BMPR2","volume":"247","author":"S\u00e1nchez-Duffhues","year":"2019","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.jacbts.2024.04.005_bib40","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3390\/genes13050759","article-title":"Reduction of BMPR2 mRNA expression in peripheral blood of pulmonary arterial hypertension patients: a marker for disease severity?","volume":"13","author":"Theobald","year":"2022","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.jacbts.2024.04.005_bib41","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/dvdy.478","article-title":"An emerging class of new therapeutics targeting TGF, activin, and BMP ligands in pulmonary arterial hypertension","volume":"252","author":"Upton","year":"2023","journal-title":"Dev Dyn"},{"key":"10.1016\/j.jacbts.2024.04.005_bib42","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1093\/cvr\/cvaa350","article-title":"Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleus","volume":"117","author":"Dunmore","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacbts.2024.04.005_bib43","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.tips.2021.04.002","article-title":"Targeting the TGF-\u03b2 signaling pathway for resolution of pulmonary arterial hypertension","volume":"42","author":"Sharmin","year":"2021","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jacbts.2024.04.005_bib44","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1183\/09031936.00187310","article-title":"Targeted gene delivery of BMPR2 attenuates pulmonary hypertension","volume":"39","author":"Reynolds","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacbts.2024.04.005_bib45","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1164\/rccm.201411-2061LE","article-title":"Low-dose FK506 (tacrolimus) in end-stage pulmonary arterial hypertension","volume":"192","author":"Spiekerkoetter","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacbts.2024.04.005_bib46","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02449-2016","article-title":"Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension","volume":"50","author":"Spiekerkoetter","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacbts.2024.04.005_bib47","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1165\/rcmb.2019-0321OC","article-title":"4PBA restores signaling of a cysteine-substituted mutant BMPR2 receptor found in patients with pulmonary arterial hypertension","volume":"63","author":"Dunmore","year":"2020","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jacbts.2024.04.005_bib48","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1161\/CIRCRESAHA.111.300483","article-title":"Chloroquine prevents progression of experimental pulmonary hypertension via inhibition of autophagy and lysosomal bone morphogenetic protein type II receptor degradation","volume":"112","author":"Long","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.jacbts.2024.04.005_bib49","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nm.3877","article-title":"Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.jacbts.2024.04.005_bib50","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1164\/rccm.201906-1141OC","article-title":"Characterization of GDF2 mutations and levels of BMP9 and BMP10 in pulmonary arterial hypertension","volume":"201","author":"Hodgson","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacbts.2024.04.005_bib51","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022327","article-title":"Bone morphogenetic protein-based therapeutic approaches","volume":"10","author":"Lowery","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.jacbts.2024.04.005_bib52","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/ten.teb.2015.0357","article-title":"A\u00a0review of the clinical side effects of bone morphogenetic protein-2","volume":"22","author":"James","year":"2016","journal-title":"Tissue Eng Part B Rev"},{"key":"10.1016\/j.jacbts.2024.04.005_bib53","doi-asserted-by":"crossref","first-page":"115551","DOI":"10.1016\/j.bone.2020.115551","article-title":"A\u00a0novel autologous bone graft substitute comprised of rhBMP6 blood coagulum as carrier tested in a randomized and controlled phase I trial in patients with distal radial fractures","volume":"140","author":"Durdevic","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.jacbts.2024.04.005_bib54","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/jbmr.4107","article-title":"Recombinant human BMP6 applied within autologous blood coagulum accelerates bone healing: randomized controlled trial in high tibial osteotomy patients","volume":"35","author":"Chiari","year":"2020","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.jacbts.2024.04.005_bib55","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1164\/rccm.201911-2137OC","article-title":"Loss of DP1 aggravates vascular remodeling in pulmonary arterial hypertension via mTORC1 signaling","volume":"201","author":"He","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacbts.2024.04.005_bib56","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/icvts\/ivx053","article-title":"Rapamycin reduced pulmonary vascular remodelling by inhibiting cell proliferation via Akt\/mTOR signalling pathway down-regulation in the carotid artery\u2013jugular vein shunt pulmonary hypertension rat model","volume":"25","author":"Ma","year":"2017","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"10.1016\/j.jacbts.2024.04.005_bib57","doi-asserted-by":"crossref","first-page":"112166","DOI":"10.1016\/j.exger.2023.112166","article-title":"Rapamycin, the only drug that has been consistently demonstrated to increase mammalian longevity. An update","volume":"176","author":"Sharp","year":"2023","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.jacbts.2024.04.005_bib58","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1089\/scd.2009.0147","article-title":"Rapamycin promotes the osteoblastic differentiation of human embryonic stem cells by blocking the mTOR pathway and stimulating the BMP\/Smad pathway","volume":"19","author":"Lee","year":"2010","journal-title":"Stem Cells Dev"},{"key":"10.1016\/j.jacbts.2024.04.005_bib59","doi-asserted-by":"crossref","first-page":"e89805","DOI":"10.1172\/jci.insight.89805","article-title":"mTOR inhibition and BMP signaling act synergistically to reduce muscle fibrosis and improve myofiber regeneration","volume":"1","author":"Agarwal","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jacbts.2024.04.005_bib60","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/1541-7786.MCR-11-0615","article-title":"Inhibition of mTORC1 kinase activates Smads 1 and 5 but not Smad8 in human prostate cancer cells, mediating cytostatic response to rapamycin","volume":"10","author":"Wahdan-Alaswad","year":"2012","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.jacbts.2024.04.005_bib61","doi-asserted-by":"crossref","first-page":"21687","DOI":"10.1074\/jbc.271.36.21687","article-title":"Characterization of the interaction of FKBP12 with the transforming growth factor-\u03b2 type i receptor in\u00a0vivo","volume":"271","author":"Okadome","year":"1996","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jacbts.2024.04.005_bib62","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1093\/hmg\/ddz047","article-title":"BMPRII deficiency impairs apoptosis via the BMPRII-ALK1-BclX\u2013mediated pathway in pulmonary arterial hypertension","volume":"28","author":"Chowdhury","year":"2019","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jacbts.2024.04.005_bib63","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/cdd.2017.183","article-title":"Why do BCL-2 inhibitors work and where should we use them in the clinic?","volume":"25","author":"Montero","year":"2018","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.jacbts.2024.04.005_bib64","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1007\/s12094-022-03070-9","article-title":"Bcl-2 pathway inhibition in solid tumors: a review of clinical trials","volume":"25","author":"Ploumaki","year":"2023","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.jacbts.2024.04.005_bib65","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3390\/antiox7110150","article-title":"Effects of Bcl-2\/Bcl-xL inhibitors on pulmonary artery smooth muscle cells","volume":"7","author":"Rybka","year":"2018","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.jacbts.2024.04.005_bib66","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1161\/CIRCULATIONAHA.122.061501","article-title":"Serum and pulmonary expression profiles of the activin signaling system in pulmonary arterial hypertension","volume":"147","author":"Guignabert","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2024.04.005_bib67","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1183\/09031936.00174908","article-title":"Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension","volume":"34","author":"Selimovic","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacbts.2024.04.005_bib68","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1161\/CIRCULATIONAHA.108.821504","article-title":"Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor\u2013like kinase-5 inhibition in prevention and progression of disease","volume":"119","author":"Long","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2024.04.005_bib69","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2353\/ajpath.2009.080565","volume":"174","author":"Thomas","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jacbts.2024.04.005_bib70","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1164\/rccm.201510-1955OC","article-title":"A\u00a0selective transforming growth factor-\u03b2 ligand trap attenuates pulmonary hypertension","volume":"194","author":"Yung","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacbts.2024.04.005_bib71","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2024.04.005_bib72","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.4049\/jimmunol.142.5.1536","article-title":"Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification","volume":"142","author":"Dasch","year":"1989","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jacbts.2024.04.005_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19102957","article-title":"Inhibitory antibodies against activin A and TGF-\u03b2 reduce self-supported, but not soluble factors-induced growth of human pulmonary arterial vascular smooth muscle cells in pulmonary arterial hypertension","volume":"19","author":"Kudryashova","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacbts.2024.04.005_bib74","doi-asserted-by":"crossref","DOI":"10.1177\/2045894019898593","article-title":"Differential effects of integrin-linked kinase inhibitor Cpd22 on severe pulmonary hypertension in male and female rats","volume":"10","author":"Shen","year":"2020","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jacbts.2024.04.005_bib75","doi-asserted-by":"crossref","first-page":"2002341","DOI":"10.1183\/13993003.02341-2020","article-title":"Targeting transforming growth factor-\u03b2 receptors in pulmonary hypertension","volume":"57","author":"Guignabert","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacbts.2024.04.005_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21239222","article-title":"Epigenetic targets for oligonucleotide therapies of pulmonary arterial hypertension","volume":"21","author":"Gerthoffer","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacbts.2024.04.005_bib77","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5660","article-title":"ACTRIIA-Fc rebalances activin\/GDF versus BMP signaling in pulmonary hypertension","volume":"12","author":"Yung","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jacbts.2024.04.005_bib78","doi-asserted-by":"crossref","DOI":"10.1038\/d41573-024-00054-y","article-title":"FDA approves Merck & Co\u2019s pulmonary arterial hypertension drug sotatercept","author":"Kingwell","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jacbts.2024.04.005_bib79","doi-asserted-by":"crossref","first-page":"15153","DOI":"10.1038\/ncomms15153","article-title":"Activin A more prominently regulates muscle mass in primates than does GDF8","volume":"8","author":"Latres","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacbts.2024.04.005_bib80","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/jcph.1638","article-title":"Pharmacokinetics and pharmacodynamics of garetosmab (anti\u2013activin A): results from a first-in-human phase 1 study","volume":"60","author":"Vanhoutte","year":"2020","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jacbts.2024.04.005_bib81","article-title":"Garetosmab, an inhibitor of activin A, reduces heterotopic ossification and flare-ups in adults with fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial","author":"di Rocco","year":"2023","journal-title":"medRxiv"},{"key":"10.1016\/j.jacbts.2024.04.005_bib82","first-page":"A4526","article-title":"RKER-012, a novel activin receptor type IIB (ActRIIB) ligand trap, reduced cardiopulmonary pathology in a rodent model of pulmonary arterial hypertension","volume":"203","author":"Babbs","year":"2021","journal-title":"Am J Respir CritCare Med"},{"key":"10.1016\/j.jacbts.2024.04.005_bib83","doi-asserted-by":"crossref","first-page":"7803","DOI":"10.1038\/s41598-022-11435-x","article-title":"Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension","volume":"12","author":"Joshi","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacbts.2024.04.005_bib84","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/153537020222700201","article-title":"Regulation of cell proliferation, apoptosis, and carcinogenesis by activin","volume":"227","author":"Chen","year":"2002","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.jacbts.2024.04.005_bib85","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.ymthe.2017.02.015","article-title":"Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes","volume":"25","author":"Mendell","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.jacbts.2024.04.005_bib86","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/mt.2014.200","article-title":"A\u00a0phase 1\/2a follistatin gene therapy trial for Becker muscular dystrophy","volume":"23","author":"Mendell","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.jacbts.2024.04.005_bib87","doi-asserted-by":"crossref","first-page":"45820","DOI":"10.1038\/srep45820","article-title":"Follistatin-like 1 protects against hypoxia-induced pulmonary hypertension in mice","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacbts.2024.04.005_bib88","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1042\/BJ20140771","article-title":"Gremlin1 preferentially binds to bone morphogenetic protein-2 (BMP-2) and BMP-4 over BMP-7","volume":"466","author":"Church","year":"2015","journal-title":"Biochem J"},{"key":"10.1016\/j.jacbts.2024.04.005_bib89","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/CIRCULATIONAHA.111.038125","article-title":"Gremlin plays a key role in the pathogenesis of pulmonary hypertension","volume":"125","author":"Cahill","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2024.04.005_bib90","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00408-015-9735-5","article-title":"Intrinsic BMP antagonist gremlin-1 as a novel circulating marker in pulmonary arterial hypertension","volume":"193","author":"Wellbrock","year":"2015","journal-title":"Lung"},{"key":"10.1016\/j.jacbts.2024.04.005_bib91","doi-asserted-by":"crossref","first-page":"e016586","DOI":"10.1161\/JAHA.120.016586","article-title":"Vital roles of gremlin-1 in pulmonary arterial hypertension induced by systemic-to-pulmonary shunts","volume":"9","author":"Meng","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacbts.2024.04.005_bib92","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.ajpath.2013.07.017","article-title":"Treatment with anti\u2013gremlin 1 antibody ameliorates chronic hypoxia\/SU5416-induced pulmonary arterial hypertension in mice","volume":"183","author":"Ciuclan","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jacbts.2024.04.005_bib93","doi-asserted-by":"crossref","first-page":"TPS221","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS221","article-title":"A\u00a0multi-modular phase I\/II study of UCB6114, a first-in-class, fully human IgG4P anti\u2013gremlin-1 monoclonal antibody, as monotherapy and in combination with mFOLFOX6 or trifluridine\/tipiracil, for patients with advanced gastrointestinal (GI) tumors","volume":"40","author":"Sarker","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacbts.2024.04.005_bib94","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.tips.2012.04.003","article-title":"Crosstalk between TGF-\u03b2 signaling and the microRNA machinery","volume":"33","author":"Butz","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jacbts.2024.04.005_bib95","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.canlet.2015.11.007","article-title":"Crosstalk between transforming growth factor-\u03b2 signaling pathway and long non-coding RNAs in cancer","volume":"370","author":"Wang","year":"2016","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jacbts.2024.04.005_bib96","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/cvr\/cvx187","article-title":"MicroRNA-424(322) as a new marker of disease progression in pulmonary arterial hypertension and its role in right ventricular hypertrophy by targeting SMURF1","volume":"114","author":"Baptista","year":"2018","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacbts.2024.04.005_bib97","doi-asserted-by":"crossref","first-page":"11406","DOI":"10.1038\/ncomms11406","article-title":"miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint","volume":"7","author":"Xu","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacbts.2024.04.005_bib98","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.omtn.2021.12.028","article-title":"miR-424\/322 protects against abdominal aortic aneurysm formation by modulating the Smad2\/3\/runt\u2013related transcription factor 2 axis","volume":"27","author":"Tsai","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jacbts.2024.04.005_bib99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0068-3","article-title":"MiR-125a-5p ameliorates monocrotaline-induced pulmonary arterial hypertension by targeting the TGF-\u03b21 and IL-6\/STAT3 signaling pathways","volume":"50","author":"Cai","year":"2018","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.jacbts.2024.04.005_bib100","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1177\/1535370215579018","article-title":"MicroRNA-125a in pulmonary hypertension: regulator of a proliferative phenotype of endothelial cells","volume":"240","author":"Huber","year":"2015","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.jacbts.2024.04.005_bib101","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00109-017-1541-5","article-title":"MiR-125a regulates mitochondrial homeostasis through targeting mitofusin 1 to control hypoxic pulmonary vascular remodeling","volume":"95","author":"Ma","year":"2017","journal-title":"J\u00a0Mol Med"},{"key":"10.1016\/j.jacbts.2024.04.005_bib102","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1756-8722-6-6","article-title":"Diverse functions of miR-125 family in different cell contexts","volume":"6","author":"Sun","year":"2013","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.jacbts.2024.04.005_bib103","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.neo.2019.06.004","article-title":"miR-125a-5p Functions as tumor suppressor microRNA and is a marker of locoregional recurrence and poor prognosis in head and neck cancer","volume":"21","author":"Vo","year":"2019","journal-title":"Neoplasia"},{"key":"10.1016\/j.jacbts.2024.04.005_bib104","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41418-021-00911-y","article-title":"miR-125a-5p attenuates macrophage-mediated vascular dysfunction by targeting Ninjurin1","volume":"29","author":"Hwang","year":"2022","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.jacbts.2024.04.005_bib105","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1164\/rccm.201106-1130OC","article-title":"Altered microRNA processing in heritable pulmonary arterial hypertension: an important role for Smad-8","volume":"184","author":"Drake","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacbts.2024.04.005_bib106","first-page":"511","article-title":"MicroRNA-21 is associated with the severity of right ventricular dysfunction in patients with hypoxia-induced pulmonary hypertension","volume":"34","author":"Chang","year":"2018","journal-title":"Acta Cardiol Sin"},{"key":"10.1016\/j.jacbts.2024.04.005_bib107","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1161\/CIRCULATIONAHA.111.060269","article-title":"MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach","volume":"125","author":"Parikh","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2024.04.005_bib108","doi-asserted-by":"crossref","first-page":"L861","DOI":"10.1152\/ajplung.00201.2010","article-title":"MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration","volume":"299","author":"Sarkar","year":"2010","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jacbts.2024.04.005_bib109","doi-asserted-by":"crossref","first-page":"L521","DOI":"10.1152\/ajplung.00316.2011","article-title":"miR-21 regulates chronic hypoxia\u2013induced pulmonary vascular remodeling","volume":"302","author":"Yang","year":"2012","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jacbts.2024.04.005_bib110","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1164\/rccm.201106-1093OC","article-title":"Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension","volume":"185","author":"Pullamsetti","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacbts.2024.04.005_bib111","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1161\/HYPERTENSIONAHA.113.03037","article-title":"Endothelial apoptosis in pulmonary hypertension is controlled by a microRNA\/programmed cell death 4\/caspase-3 axis","volume":"64","author":"White","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.jacbts.2024.04.005_bib112","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1161\/ATVBAHA.109.202028","article-title":"Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline","volume":"30","author":"Caruso","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacbts.2024.04.005_bib113","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.omtn.2021.09.007","article-title":"Inhibition of microRNA-30a alleviates vascular remodeling in pulmonary arterial hypertension","volume":"26","author":"Ma","year":"2021","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jacbts.2024.04.005_bib114","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1074\/jbc.M111.292722","article-title":"miR-30 family members negatively regulate osteoblast differentiation","volume":"287","author":"Wu","year":"2012","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jacbts.2024.04.005_bib115","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/pros.23184","article-title":"Activin A regulates microRNAs and gene expression in LNCaP cells","volume":"76","author":"Ottley","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.jacbts.2024.04.005_bib116","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3389\/fgene.2019.00478","article-title":"The potential for microRNA therapeutics and clinical research","volume":"10","author":"Hanna","year":"2019","journal-title":"Front Genet"},{"key":"10.1016\/j.jacbts.2024.04.005_bib117","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/cvr\/cvw054","article-title":"Exosomes induce and reverse monocrotaline-induced pulmonary hypertension in mice","volume":"110","author":"Aliotta","year":"2016","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacbts.2024.04.005_bib118","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1161\/CIRCRESAHA.109.197491","article-title":"Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17\/92 pathway","volume":"104","author":"Brock","year":"2009","journal-title":"Circ Res"},{"key":"10.1016\/j.jacbts.2024.04.005_bib119","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1161\/CIRCRESAHA.112.267591","article-title":"A\u00a0role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples","volume":"111","author":"Caruso","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.jacbts.2024.04.005_bib120","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.3390\/cells10081892","article-title":"Role of long non-coding RNAs in pulmonary arterial hypertension","volume":"10","author":"Han","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jacbts.2024.04.005_bib121","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1161\/CIRCULATIONAHA.120.047626","article-title":"Identification of long noncoding RNA H19 as a new biomarker and therapeutic target in right ventricular failure in pulmonary arterial hypertension","volume":"142","author":"Omura","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2024.04.005_bib122","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1002\/stem.2225","article-title":"Long noncoding RNA H19 promotes osteoblast differentiation via TGF-\u03b21\/Smad3\/HDAC signaling pathway by deriving miR-675","volume":"33","author":"Huang","year":"2015","journal-title":"Stem Cells"},{"key":"10.1016\/j.jacbts.2024.04.005_bib123","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41467-021-21961-3","article-title":"An endothelial activin A\u2013bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertension","volume":"12","author":"Ryanto","year":"2021","journal-title":"Nature Communications"},{"key":"10.1016\/j.jacbts.2024.04.005_bib124","first-page":"1099","article-title":"Extracellular vesicles in pulmonary hypertension: a dangerous liaison?","volume":"12","author":"Conti","year":"2023","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.jacbts.2024.04.005_bib125","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12964-019-0449-9","article-title":"Extracellular vesicle cross-talk between pulmonary artery smooth muscle cells and endothelium during excessive TGF-\u03b2 signalling: implications for PAH vascular remodelling","volume":"17","author":"de la Cuesta","year":"2019","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.jacbts.2024.04.005_bib126","doi-asserted-by":"crossref","first-page":"103444","DOI":"10.1016\/j.ebiom.2021.103444","article-title":"A\u00a0diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach","volume":"69","author":"Errington","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jacbts.2024.04.005_bib127","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension","volume":"384","author":"Humbert","year":"2021","journal-title":"N\u00a0Engl J Med"}],"container-title":["JACC: Basic to Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X24001748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X24001748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T14:09:27Z","timestamp":1732543767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452302X24001748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":127,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2452302X24001748"],"URL":"https:\/\/doi.org\/10.1016\/j.jacbts.2024.04.005","relation":{},"ISSN":["2452-302X"],"issn-type":[{"value":"2452-302X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting Soluble TGF-\u03b2 Factors","name":"articletitle","label":"Article Title"},{"value":"JACC: Basic to Translational Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacbts.2024.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}